The company's Neulasta biosimilar has generated $232 million in revenue in the first nine months of 2019, but its growth rate will slow soon.
Disappointing early sales results for its newest treatments, Rhopressa and Rocklatan, haven't shaken the company's confidence. Wall Street is a different story.
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.
A large percentage of patients prescribed the biotech's lone drug stop taking it early. Can two changes to its dosing protocols solve that problem?
The company encountered a delay for its most important clinical trial, but still expects six data readouts for three pipeline assets in the next seven months.
The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.
The gene-editing company rallied investors around intriguing clinical data released earlier this month, and the rally hasn't stopped.
Ramping up production of its zero-calorie sweetener has proved expensive. Can the company rein in costs?
The company set several quarterly records and sees ample opportunities for growth in 2020, but expects to come in at the low end of full-year 2019 guidance.
Shares of the lithium producer are trading at three-year lows, but the company might receive a significant windfall in 2020 that the markets couldn't ignore.
A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.
The lab-instrument developer reported that sales of its leading growth product declined from the third quarter of 2018. Is competition to blame?
Highly anticipated clinical trial results didn't continue a promising trend from a smaller number of patients.
Despite nearly meeting its full-year 2019 product revenue guidance after just three quarters, the company didn't raise guidance. What does that mean?
The company encountered a delay in an important clinical trial, but it will lead to better outcomes for patients in the long run.
The company reported positive results in a late-stage trial for an important drug candidate.
The gene-editing pioneer provided investors with an encouraging quarterly update.
Investors grew optimistic that the company's legal and financial risks from the ongoing opioid epidemic may be coming to an end.
The company reported third-quarter 2019 operating results and raised full-year 2019 guidance for its lead drug product.
The company reported third-quarter 2019 operating results and deepened its relationship with Gilead Sciences.